Compare INNV & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | NVAX |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2021 | 1996 |
| Metric | INNV | NVAX |
|---|---|---|
| Price | $10.75 | $9.33 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $11.33 |
| AVG Volume (30 Days) | 219.3K | ★ 5.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 90.91 | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | $989,707,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $12.85 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.93 | ★ 64.69 |
| 52 Week Low | $3.94 | $6.20 |
| 52 Week High | $12.64 | $11.85 |
| Indicator | INNV | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 56.71 |
| Support Level | $7.33 | $8.42 |
| Resistance Level | $11.97 | $10.10 |
| Average True Range (ATR) | 0.52 | 0.61 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 27.41 | 37.64 |
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.